15 completed. 15 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Completed 15 |
| Phase 2 | 4 | Completed 4 |
Follow Hypertrophy: new trials by email Literature Review of Hypertrophy trials Research Report on Hypertrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Silicone Gel Versus Onion Extract Gel as Prevention for Postsurgical Scars Silicone gel Kelo-cort™;, Onion extract gel Contractubex™ - Hypertrophic or Keloid Scars | Phase 3 | Completed | CHA University | 90 | 2013-04-01 | 2019-08-28 |
| Running Effect on Cardiovascular and Muscular Parameters exercise - Males, Untrained | Phase 3 | Completed | University of Erlangen-Nürnberg Medical School | 80 | 2011-07-01 | 2012-08-14 |
| Angiotensin-converting-enzyme (ACE) Inhibitors in Hemodialysis ACE inhibitor Ramipril, non-RAS inhibitor antihypertensive therapy - Left Ventricular Hypertrophy, Hypertension | Phase 3 | Completed | Mario Negri Institute for Pharmacological Research | 269 | 2009-05-01 | 2021-01-11 |
| Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease spironolactone, placebo - Primary Hypertension | Phase 3 | Completed | University of Erlangen-Nürnberg Medical School | 50 | 2008-03-01 | 2012-07-10 |
| The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4 paricalcitol, placebo - Chronic Kidney Disease, Left Ventricular Hypertrophy | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 227 | 2008-02-01 | 2013-03-12 |
| Lanreotide as Treatment of Polycystic Livers Placebo, Lanreotide - Polycystic Liver Disease, Hepatomegaly | Phase 2 / Phase 3 | Completed | Radboud University Medical Center | 38 | 2007-10-01 | 2009-02-17 |
| Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy Valsartan, Amlodipine, Hydrochlorothiazide - Hypertension; Hypertrophy, Left Ventricular | Phase 3 | Completed | Novartis | 90 | 2007-03-01 | 2011-05-11 |
| Octreotide in Severe Polycystic Liver Disease Octreotide, Placebo - Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease | Phase 2 / Phase 3 | Completed | Mayo Clinic | 42 | 2007-01-01 | 2012-11-21 |
| Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem Diltiazem, Placebo - Hypertrophic Cardiomyopathy | Phase 2 / Phase 3 | Completed | Brigham and Women's Hospital | 39 | 2006-01-01 | 2015-04-07 |
| Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension Aliskiren 150/300 mg, Losartan 50/100 mg, Aliskiren placebo - Hypertension, Left Ventricular Hypertrophy | Phase 3 | Completed | Novartis Pharmaceuticals | 460 | 2005-10-01 | 2011-05-26 |
| The CLEVER Study - Coreg And Left Ventricular Mass Regression carvedilol MR, atenolol, lisinopril - Hypertrophy, Left Ventricular | Phase 3 | Completed | GlaxoSmithKline | 287 | 2005-01-01 | 2016-12-16 |
| Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients ACE Inhibition, Intensified Blood Pressure Control, Add-on Angiotensin Receptor Blockade - Children, Chronic Renal Failure | Phase 3 | Completed | Heidelberg University | 400 | 1998-01-01 | 2010-01-12 |
| A Safety and Efficacy Study for Epoetin Alfa in Pre-dialysis Subjects. epoetin alfa - Anemia, Kidney Failure | Phase 3 | Completed | Janssen-Ortho Inc., Canada | 172 | 1997-12-01 | 2011-02-01 |
| Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133) MK0954, /Duration of Treatment : 5 Years, Comparator : atenolol /Duration of Treatment : 5 Years - Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart) | Phase 3 | Completed | Organon and Co | 496 | 1995-06-01 | 2022-02-15 |
| Irbesartan and Atenolol in Hypertensive Heart Disease Irbesartan, Atenolol - Hypertension | Phase 2 / Phase 3 | Completed | Karolinska Institutet | 115 | 1995-04-01 | 2015-05-05 |
Hypertrophy, Left Ventricular (10) · Hypertension (6) · Cardiomegaly (2) · Hepatomegaly (2) · Liver Diseases (2) · Polycystic Kidney, Autosomal Dominant (2) · Polycystic liver disease (2) · Abdominal Pain (1) · Anemia (1) · Cardiomyopathy, Hypertrophic (1) · Cardiovascular Diseases (1) · Disease Progression (1) · Essential Hypertension (1) · Keloid (1)
Pathological Conditions, Anatomical (15) · Pathological Conditions, Signs and Symptoms (15) · Heart Diseases (12) · Cardiovascular Diseases (11) · Cardiomegaly (10) · Vascular Diseases (7) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Kidney Diseases (5) · Male Urogenital Diseases (5) · Urogenital Diseases (5) · Urologic Diseases (5) · Pathologic Processes (3) · Abnormalities, Multiple (2)
Atenolol (2) · Losartan (2) · Amlodipine (1) · Diltiazem (1) · Duration of Therapy (1) · Epoetin Alfa (1) · Exercise (1) · Hydrochlorothiazide (1) · Irbesartan (1) · Lisinopril (1) · Octreotide (1) · Ramipril (1) · Spironolactone (1) · Telmisartan (1) · Valsartan (1)
University of Erlangen-Nürnberg Medical School (2) · AbbVie (prior sponsor, Abbott) (1) · Brigham and Women's Hospital (1) · CHA University (1) · GlaxoSmithKline (1) · Heidelberg University (1) · Janssen-Ortho Inc., Canada (1) · Karolinska Institutet (1) · Mario Negri Institute for Pharmacological Research (1) · Mayo Clinic (1) · Novartis (1) · Novartis Pharmaceuticals (1) · Organon and Co (1) · Radboud University Medical Center (1)
Germany (6) · United States (5) · Italy (4) · Sweden (3) · Czechia (2) · Poland (2) · Russia (2) · Spain (2) · Argentina (1) · Australia (1) · Belgium (1) · Colombia (1) · Finland (1) · France (1) · Hungary (1)
Ann Eldred, MD (1) · Carolyn Y Ho, MD (1) · Franz Schaefer, MD (1) · Frederik Nevens, MD, PhD (1) · Joost PH Drenth, MD, PhD (1) · Loes van Keimpema, MSc (1) · Marie C. Hogan, M.D., Ph.D. (1) · Michael Lell, MD (1) · Michael Scharf, MD (1) · Michael Uder, MD (1)
PMID 39356039, PMID 11403367, PMID 12172314, PMID 12423712, PMID 14630977, PMID 14639093, PMID 14700505, PMID 14704728, PMID 14744931, PMID 15253732, PMID 15647341, PMID 15716707, PMID 15772249, PMID 16093916, PMID 16253719, PMID 16942935, PMID 17444886, PMID 17637792, PMID 17762662, PMID 18464745, PMID 18591942, PMID 19332468, PMID 19486119, PMID 20001655, PMID 20589977, PMID 20601389, PMID 21239405, PMID 21242674, PMID 21304095, PMID 21358415, PMID 21720264, PMID 21746765, PMID 22243363, PMID 22337679, PMID 22695506, PMID 22753219, PMID 22773240, PMID 23194491, PMID 23403268, PMID 24084214, PMID 24379001, PMID 24723582, PMID 25340854, PMID 25873721, PMID 26056336, PMID 26089332, PMID 26166166, PMID 26378687, PMID 27536421, PMID 27590665
2008 (1), K23HL078901 (1), UL1RR024150 (1)